Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Cyclophosphamide/adverse effects"'
Autor:
Victoria, Corvest, Perrine, Marec-Bérard, Cyril, Lervat, Hélène, Pacquement, Maud, Toulmonde, Jean-Claude, Gentet, Valérie, Laurence, Morgane, Cleirec, Ludovic, Mansuy, Emmanuelle, Bompas, Marie-Pierre, Castex, Sophie, Taque, Bruno, Filhon, Marie-Dominique, Tabone, Cécile, Verité, Natacha, Entz-Werle, Laure, Saumet, Gregory, Guimard, Morgane, Pondrom, Christine, Chevreau, Jennifer, Flandrin, Lise, Duranteau, Christine, Rousset-Jablonski, Laurence, Brugières, Marta, Jimenez, Marie-Cécile, Le Deley, Nathalie, Gaspar, Brice, Fresneau
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 2023, 152 (8), pp.1659-1667. ⟨10.1002/ijc.34326⟩
International Journal of Cancer, 2023, 152 (8), pp.1659-1667. ⟨10.1002/ijc.34326⟩
International audience; In Euro-EWING99-R1 randomized trial, cyclophosphamide was shown to be noninferior to ifosfamide in the consolidation of standard-risk Ewing sarcoma (SR-EWS) after a common induction with VIDE (vincristine-ifosfamide-doxorubici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7b644a71781b07ef0847fe0f23b11b80
https://hal.science/hal-04122360/document
https://hal.science/hal-04122360/document
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Urs Schanz, Claire Seydoux, Nathan Cantoni, Patrick Simon, Stavroula Masouridi Levrat, Sabine Gerull, Joerg Halter, Michael Medinger, Yves Chalandon, Gayathri Nair, Dominik Heim, Marc Ansari, Jakob Passweg
Publikováno v:
Annals of Hematology
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior
Autor:
Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz
Publikováno v:
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
Autor:
Joanna M Oladipo, Hannah Plaschkes, Paul Fields, Arief Gunawan, Amy A Kirkwood, John Willan, Bing Tseu, Catherine Hildyard, Tim Ebsworth, Lucia Chen, Usman Khan, Robert Lown, Joe Browning, Adam Gibb, Patrick Horgan, Julia Wolf, Kim Linton, Jaimal Kothari, Dominic Gordon-Walker, Nimish Shah, Claire Higham, Graham P. Collins, Stephen Booth, Toby A. Eyre
Publikováno v:
Booth, S, Plaschkes, H, Kirkwood, A A, Gibb, A, Horgan, P, Higham, C, Oladipo, J M, Browning, J, Khan, U, Tseu, B, Chen, L, Willan, J, Wolf, J, Gunawan, A, Fields, P, Ebsworth, T, Lown, R, Gordon-Walker, D, Shah, N, Linton, K M, Collins, G P, Kothari, J, Hildyard, C & Eyre, T A 2020, ' Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma ', Blood Advances, vol. 4, no. 18, pp. 4337-4346 . https://doi.org/10.1182/BLOODADVANCES.2020002553
Blood Adv
Blood Adv
Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture are both more common in older patients. Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc9701b57b526dc42a68d328f065ff7
https://research.manchester.ac.uk/en/publications/eb959c06-89d1-46b1-aa0f-dda1a7688dd4
https://research.manchester.ac.uk/en/publications/eb959c06-89d1-46b1-aa0f-dda1a7688dd4
Autor:
Thomas Creasey, Nimish Shah, Jeremy Schofield, Kate Cwynarski, Matthew R. Wilson, Jeffery Smith, Toby A. Eyre, Cheuk Kie Cheung, Fiona Miall, Kim Linton, Katrina Parsons, Christopher P. Fox, Gavin Preston, Pamela McKay, Matthew J. Ahearne, Matthew A. Timmins, Almurtadha Mula Kh, Jahanzaib Khwaja, Nicolas Martinez-Calle, Johnathon Elliot
Publikováno v:
Blood Adv
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421
High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to intercalate HD-MT
Autor:
Souza, Cláudio Antônio de, Simões, Ricardo, Borges, Karina Braga Gomes, Oliveira, Angélica Navarro de, Zogeib, Juliana Barroso, Alves, Bruno, Malachias, Marcus Vinicius Bolívar, Drummond-Lage, Ana Paula, Rezende, Bruno Almeida
Publikováno v:
Arquivos Brasileiros de Cardiologia, Volume: 111, Issue: 5, Pages: 721-728, Published: 21 SEP 2018
Background: Chemotherapy with doxorubicin and cyclophosphamide, although efficient for treating breast cancer, is associated with cardiovascular complications. Recent studies seek to identify methods that can early detect cardiological and vascular c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______608::1d4bd560bf3f56b4b5c0a56293559d80
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2018001700721&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2018001700721&lng=en&tlng=en
Publikováno v:
Acta Cirúrgica Brasileira v.33 n.6 2018
Acta Cirúrgica Brasileira
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)
instacron:SBDPC
Acta Cirurgica Brasileira, Volume: 33, Issue: 6, Pages: 499-507, Published: JUN 2018
Acta Cirurgica Brasileira, Vol 33, Iss 6, Pp 499-507 (2018)
Acta Cirúrgica Brasileira
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)
instacron:SBDPC
Acta Cirurgica Brasileira, Volume: 33, Issue: 6, Pages: 499-507, Published: JUN 2018
Acta Cirurgica Brasileira, Vol 33, Iss 6, Pp 499-507 (2018)
Purpose: To evaluate the impact of systemic cyclophosphamide treatment on the rat uterus and investigate the potential therapeutic effects of natural antioxidant preparations curcumin and capsaicin against cyclophosphamide side effects. Methods: A 40
Autor:
Bruno José Rodrigues Alves, Bruno A. Rezende, Karina Braga Gomes Borges, Ana Paula Drummond-Lage, Marcus Vinícius Bolívar Malachias, Ricardo Simões, Juliana Barroso Zogeib, Cláudio Antônio de Souza, Angélica Navarro de Oliveira
Publikováno v:
Arquivos Brasileiros de Cardiologia
Arquivos Brasileiros de Cardiologia v.111 n.5 2018
Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
Arquivos Brasileiros de Cardiologia, Issue: ahead, Published: 21 SEP 2018
Arquivos Brasileiros de Cardiologia, Iss 0 (2018)
Arquivos Brasileiros de Cardiologia v.111 n.5 2018
Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
Arquivos Brasileiros de Cardiologia, Issue: ahead, Published: 21 SEP 2018
Arquivos Brasileiros de Cardiologia, Iss 0 (2018)
Background: Chemotherapy with doxorubicin and cyclophosphamide, although efficient for treating breast cancer, is associated with cardiovascular complications. Recent studies seek to identify methods that can early detect cardiological and vascular c
Autor:
Kijima, Toshiki, Masuda, Hitoshi, Suzuki, Masahito, Okada, Yohei, Yano, Masataka, Hyochi, Nobuhiko, Fujii, Yasuhisa, Kawakami, Satoru, Hayashi, Tetsuo, Kobayashi, Tsuyoshi, Kihara, Kazunori
Publikováno v:
泌尿器科紀要. 49(8):483-486
症例1(36歳女), 症例2(63歳男)はWegener肉芽腫症に対し, 11年間にそれぞれ計104g, 100gのシクロホスファミド(CPM)の投与を受けた.症例3(50歳女)は再発性乳癌に対し, 計57gのCPM投与を受けた.3例とも